Related references
Note: Only part of the references are listed.Histone Deacetylase Inhibitors as Anticancer Drugs
Tomas Eckschlager et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
被撤回的出版物: Proteasome inhibitors in glioblastoma (Retracted article. See vol. 14, pg. 6321, 2017)
Wen-Juan Huang et al.
ONCOLOGY LETTERS (2017)
HDAC inhibitors enhance the immunotherapy response of melanoma cells
Laurence Booth et al.
ONCOTARGET (2017)
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Roberta Mazzone et al.
CLINICAL EPIGENETICS (2017)
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Roberto Pili et al.
CLINICAL CANCER RESEARCH (2017)
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
Ashley Orillion et al.
CLINICAL CANCER RESEARCH (2017)
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities
Kate Roberts et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Error-Prone Repair of DNA Double-Strand Breaks
Kasey Rodgers et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success
John A. Halsall et al.
BIOESSAYS (2016)
Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer
Marios P. Decatris et al.
FUTURE ONCOLOGY (2016)
Anticancer metal drugs and immunogenic cell death
Alessio Terenzi et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Histone deacetylase inhibitors as immunomodulators in cancer therapeutics
Li Shen et al.
EPIGENOMICS (2016)
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
Sofia R. Gameiro et al.
ONCOTARGET (2016)
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
Yusuke Tomita et al.
ONCOIMMUNOLOGY (2016)
Trial watch - inhibiting PARP enzymes for anticancer therapy
Antonella Sistigu et al.
MOLECULAR & CELLULAR ONCOLOGY (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Denise Niewerth et al.
DRUG RESISTANCE UPDATES (2015)
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Madhusoodanan Mottamal et al.
MOLECULES (2015)
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
K. Cao et al.
ONCOGENE (2015)
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
David M. Woods et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors
Emanuela Romano et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review
Ahmed Sawas et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2015)
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials
Dharam Kaushik et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
Sridurga Mithraprabhu et al.
EPIGENETICS (2014)
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism
Kwai Fung Hui et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Epigenetic regulation in cancer progression
Eva Baxter et al.
CELL AND BIOSCIENCE (2014)
Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising
Christian Jekimovs et al.
FRONTIERS IN ONCOLOGY (2014)
New Mechanistic and Functional Insights into DNA Topoisomerases
Stefanie Hartman Chen et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 82 (2013)
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
B. Groselj et al.
BRITISH JOURNAL OF CANCER (2013)
Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer
Himashinie V. K. Diyabalanage et al.
CANCER LETTERS (2013)
Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
K. Ted Thurn et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Concise Drug Review: Azacitidine and Decitabine
Ellen J. B. Derissen et al.
ONCOLOGIST (2013)
Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells
Weiwei Xiao et al.
PLOS ONE (2013)
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
Berkley E. Gryder et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition
Amila Suraweera et al.
MOLECULAR CELL (2012)
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
S. Spiegel et al.
ONCOGENE (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Kenji Takeuchi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2011)
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2011)
Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky et al.
CANCER (2011)
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
K. Ted Thurn et al.
FUTURE ONCOLOGY (2011)
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
Jacob E. Shabason et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
The Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line
Cheol Yong Yoon et al.
JOURNAL OF UROLOGY (2011)
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
Teru Hideshima et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance
Robert W. Robey et al.
MOLECULAR PHARMACEUTICS (2011)
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
Yoshihiro Minamiya et al.
LUNG CANCER (2011)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L. R. Molife et al.
ANNALS OF ONCOLOGY (2010)
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
U. Lassen et al.
BRITISH JOURNAL OF CANCER (2010)
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
Daniela Buglio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
Dana Rathkopf et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
Richard A. Campbell et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Cliona Grant et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Enrique M. Ocio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
J-H. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
An In Vitro Model for Preclinical Testing of Endocrine Therapy Combinations for Prostate Cancer
Minja J. Pfeiffer et al.
PROSTATE (2010)
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Julia M. Wagner et al.
Clinical Epigenetics (2010)
Cellular Responses to Cisplatin-Induced DNA Damage
Alakananda Basu et al.
JOURNAL OF NUCLEIC ACIDS (2010)
ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)
S. E. Witta et al.
ANNALS OF ONCOLOGY (2009)
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Daniel Finley
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2009)
Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (National Cancer Institute Trial 6862) Trial Results and Interleukin-6 Analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
Deborah Bradley et al.
CANCER (2009)
Histone deacetylase inhibitors and genomic instability
Gregory Eot-Houllier et al.
CANCER LETTERS (2009)
Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma
Gonzalo Lopez et al.
CLINICAL CANCER RESEARCH (2009)
Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
Ina Oehme et al.
CLINICAL CANCER RESEARCH (2009)
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
Pamela Munster et al.
CLINICAL CANCER RESEARCH (2009)
Successful Treatment of Anaplastic Thyroid Carcinoma with a Combination of Oral Valproic Acid, Chemotherapy, Radiation and Surgery
Hitoshi Noguchi et al.
ENDOCRINE JOURNAL (2009)
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors
H. Miles Prince et al.
FUTURE ONCOLOGY (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
Douglas C. Marchion et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Finding the place of histone deacetylase inhibitors in prostate cancer therapy
Deborah L Marrocco-Tallarigo et al.
Expert Review of Clinical Pharmacology (2009)
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
W. Weichert et al.
BRITISH JOURNAL OF CANCER (2008)
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
L. Nolan et al.
BRITISH JOURNAL OF CANCER (2008)
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma
Valeria R. Fantin et al.
CANCER RESEARCH (2008)
Novel cytotoxic drugs: Old challenges, new solutions
Gustavo F. V. Ismae et al.
CANCER TREATMENT REVIEWS (2008)
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation
Guo Zhang et al.
CLINICAL CANCER RESEARCH (2008)
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Thehang H. Luu et al.
CLINICAL CANCER RESEARCH (2008)
Histone deacetylase inhibitors in cancer therapy
Min-Jung Lee et al.
CURRENT OPINION IN ONCOLOGY (2008)
DNA Methylation: Its Role in Cancer Development and Therapy
Carlo Kurkjian et al.
CURRENT PROBLEMS IN CANCER (2008)
Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer
Mari Bjorkman et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells
Marielle Dejligbjerg et al.
MOLECULAR CANCER (2008)
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
Akihiko Miyanaga et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer:: a retrospective analysis
Wilko Weichert et al.
LANCET ONCOLOGY (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas
Wilko Weichert et al.
NEOPLASIA (2008)
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications
Valeria R. Fantin et al.
CLINICAL CANCER RESEARCH (2007)
Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines
Chandra M. Das et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Optimizing combination chemotherapy by controlling drug ratios
Lawrence D. Mayer et al.
MOLECULAR INTERVENTIONS (2007)
Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2007)
Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines
Jun Shen et al.
BIOCHEMICAL PHARMACOLOGY (2007)
The role of histone deacetylases (HDACs) in human cancer
Santiago Ropero et al.
MOLECULAR ONCOLOGY (2007)
被撤回的出版物: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation (Retracted article. See vol. 78, pg. 4097, 2018)
Chang-Shi Chen et al.
CANCER RESEARCH (2007)
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors:: A clinical and translational study
Pamela Muenster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma
Sascha Venturelli et al.
CANCER (2007)
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells
Alessandra Valentini et al.
CANCER BIOLOGY & THERAPY (2007)
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy
A. L. Goldberg
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Non-Hodgkin lymphoma secondary to cancer chemotherapy
Biju Krishnan et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Deborah L. Marrocco et al.
MOLECULAR CANCER THERAPEUTICS (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Guillermo Garcia-Manero et al.
BLOOD (2006)
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors
Manisha H. Shah et al.
CLINICAL CANCER RESEARCH (2006)
Targeting histone deacetylase in cancer therapy
Hsiang-Yu Lin et al.
MEDICINAL RESEARCH REVIEWS (2006)
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
SD Gore et al.
CANCER RESEARCH (2006)
Modulation of cellular radiation responses by histone deacetylase inhibitors
T. C. Karagiannis et al.
ONCOGENE (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ
DC Marchion et al.
CLINICAL CANCER RESEARCH (2005)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
ZH Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid
H Yang et al.
LEUKEMIA RESEARCH (2005)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies
MA Rudek et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins
DC Marchion et al.
CANCER RESEARCH (2005)
Cyclin D1 inhibits peroxisome proliferator-activated receptor γ-mediated adipogenesis through histone deacetylase recruitment
MF Fu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Y Pommier et al.
ONCOGENE (2004)
Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells
N Saleh-Gohari et al.
NUCLEIC ACIDS RESEARCH (2004)
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors
XY Pei et al.
CLINICAL CANCER RESEARCH (2004)
The Sir2 family of protein deacetylases
G Blander et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2004)
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamine acid
DC Marchion et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses
K Rothkamm et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Histone deacetylases and cancer: Causes and therapies
PA Marks et al.
NATURE REVIEWS CANCER (2001)
ATM, a central controller of cellular responses to DNA damage
KK Khanna et al.
CELL DEATH AND DIFFERENTIATION (2001)
DNA double-strand breaks: signaling, repair and the cancer connection
KK Khanna et al.
NATURE GENETICS (2001)
The role of the redox protein thioredoxin in cell growth and cancer
G Powis et al.
FREE RADICAL BIOLOGY AND MEDICINE (2000)
Share Paper
